Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus COVERA HS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus COVERA HS.
ADALAT vs COVERA-HS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker